Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Genenta Science (GNTA) and Anemocyte announced a strategic collaboration with a focus on off-the-shelf lentiviral vector Plasmid DNA technology ...

Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, ...

Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...

Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.

ROCKVILLE, Md., Oct. 8, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company's ...

For Research Use Only. Not for use in diagnostic procedures. The purification of plasmid DNA (pDNA) is essential in molecular biology research. Over the years, plasmid DNA isolation technology has ...

Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with ...